neutral
2 days agoSudeep Pharma Surges on Market Debut After Listing Nearly 24% Above Issue Price
Sudeep Pharma made a strong stock market debut today, listing at a 24% premium to its IPO price of ₹593. The stock opened at ₹733.95 on the BSE and ₹730 on the NSE, reflecting healthy investor appetite. The company raised ₹895 crore through a combination of fresh issuance and an offer for sale. Its IPO was subscribed 93.71 times overall, led by QIB demand at 213.08 times, underscoring confidence in its high-entry-barrier excipients and speciality nutrition portfolio.
Explore:Mutual Fund Home
neutral
2 days agoSudeep Pharma Surges on Market Debut After Listing Nearly 24% Above Issue Price
Sudeep Pharma made a strong stock market debut today, listing at a 24% premium to its IPO price of ₹593. The stock opened at ₹733.95 on the BSE and ₹730 on the NSE, reflecting healthy investor appetite. The company raised ₹895 crore through a combination of fresh issuance and an offer for sale. Its IPO was subscribed 93.71 times overall, led by QIB demand at 213.08 times, underscoring confidence in its high-entry-barrier excipients and speciality nutrition portfolio.
1 min read
77 words
Sudeep Pharma listed with a 24% premium after a heavily subscribed IPO, driven by strong QIB participation and confidence in its excipients and speciality nutrition business.
Sudeep Pharma made a strong stock market debut today, listing at a 24% premium to its IPO price of ₹593. The stock opened at ₹733.95 on the BSE and ₹730 on the NSE, reflecting healthy investor appetite. The company raised ₹895 crore through a combination of fresh issuance and an offer for sale. Its IPO was subscribed 93.71 times overall, led by QIB demand at 213.08 times, underscoring confidence in its high-entry-barrier excipients and speciality nutrition portfolio.
Sudeep Pharma made a strong stock market debut today, listing at a 24% premium to its IPO price of ₹593. The stock opened at ₹733.95 on the BSE and ₹730 on the NSE, reflecting healthy investor appetite. The company raised ₹895 crore through a combination of fresh issuance and an offer for sale. Its IPO was subscribed 93.71 times overall, led by QIB demand at 213.08 times, underscoring confidence in its high-entry-barrier excipients and speciality nutrition portfolio.
Nov 28, 2025 • 09:28